<?xml version="1.0" encoding="utf-8"?>
<feed xmlns="http://www.w3.org/2005/Atom">
  <title>perfectplaintiff.com: settlement amounts disclosed in company filings</title>
  <subtitle>Settlement amounts quoted word for word from companies' filings with the Securities and Exchange Commission.</subtitle>
  <id>https://perfectplaintiff.com/alerts/settlements.xml</id>
  <link rel="self" type="application/atom+xml" href="https://perfectplaintiff.com/alerts/settlements.xml"/>
  <link rel="alternate" type="text/html" href="https://perfectplaintiff.com/newsroom/settlements/"/>
  <updated>2025-04-08T00:00:00Z</updated>
  <author><name>perfectplaintiff.com</name></author>
  <entry>
    <title>Jazz Pharmaceuticals plc stated a settlement amount of $145,000,000: Xyrem (Sodium Oxybate) Antitrust Litigation</title>
    <id>tag:perfectplaintiff.com,2025-04-08:settlement/2966/2025-04-08/0</id>
    <link rel="alternate" type="text/html" href="https://perfectplaintiff.com/newsroom/settlements/"/>
    <updated>2025-04-08T00:00:00Z</updated>
    <summary>In a form 8-K filed with the Securities and Exchange Commission on 2025-04-08, Jazz Pharmaceuticals plc stated: &quot;Pursuant to the preliminary class settlement agreement, which was entered into with counsel representing the class representatives, the Company has agreed to pay a total of $145 million in a lump sum.&quot; This is what the company told investors on that date.</summary>
  </entry>
  <entry>
    <title>23andMe Holding Co. stated a settlement amount of $30,000,000: 23andMe, Inc., Customer Data Security Breach Litigation</title>
    <id>tag:perfectplaintiff.com,2025-01-28:settlement/3098/2025-01-28/1</id>
    <link rel="alternate" type="text/html" href="https://perfectplaintiff.com/mass-torts/23andme-inc-customer-data-security-breach-litigation-mdl-3098/"/>
    <updated>2025-01-28T00:00:00Z</updated>
    <summary>In a form 8-K filed with the Securities and Exchange Commission on 2025-01-28, 23andMe Holding Co. stated: &quot;On December 4, 2024, the U.S. District Court for the Northern District of California granted preliminary conditional approval of the previously announced settlement agreement under which the Company would agree to pay $30 million and implement certain remedial measures to resolve all claims by U.S. customers (who do not opt out) arising out of the Company's cyber security incident disclosed in October 2023.&quot; This is what the company told investors on that date.</summary>
  </entry>
  <entry>
    <title>Johnson Controls International plc stated a settlement amount of $750,000,000: Aqueous Film-Forming Foams Products Liability Litigation</title>
    <id>tag:perfectplaintiff.com,2024-04-12:settlement/2873/2024-04-12/2</id>
    <link rel="alternate" type="text/html" href="https://perfectplaintiff.com/mass-torts/aqueous-film-forming-foams-products-liability-litigation-mdl-2873/"/>
    <updated>2024-04-12T00:00:00Z</updated>
    <summary>In a form 8-K filed with the Securities and Exchange Commission on 2024-04-12, Johnson Controls International plc stated: &quot;Under the terms of the agreement, Tyco agreed to contribute $750 million to resolve these PFAS claims.&quot; This is what the company told investors on that date.</summary>
  </entry>
  <entry>
    <title>Kroger Co stated a settlement amount of $1,200,000,000: National Prescription Opiate Litigation</title>
    <id>tag:perfectplaintiff.com,2023-09-08:settlement/2804/2023-09-08/3</id>
    <link rel="alternate" type="text/html" href="https://perfectplaintiff.com/mass-torts/national-prescription-opiate-litigation-mdl-2804/"/>
    <updated>2023-09-08T00:00:00Z</updated>
    <summary>In a form 8-K filed with the Securities and Exchange Commission on 2023-09-08, Kroger Co stated: &quot;Along with the execution of certain non-monetary conditions that remain in discussion, Kroger has agreed to pay up to $1.2 billion to states and subdivisions and $36 million to Native American tribes in funding for abatement efforts (both to be paid over 11 years in equal installments), and approximately $177 million to cover attorneys' fees and costs (to be paid over 6 years in equal installments).&quot; This is what the company told investors on that date.</summary>
  </entry>
  <entry>
    <title>3M Co stated a settlement amount of $6,010,000,000: 3M Combat Arms Earplug Products Liability Litigation</title>
    <id>tag:perfectplaintiff.com,2023-08-29:settlement/2885/2023-08-29/4</id>
    <link rel="alternate" type="text/html" href="https://perfectplaintiff.com/mass-torts/3m-combat-arms-earplug-products-liability-litigation-mdl-2885/"/>
    <updated>2023-08-29T00:00:00Z</updated>
    <summary>In a form 8-K filed with the Securities and Exchange Commission on 2023-08-29, 3M Co stated: &quot;Pursuant to the Settlement, reached through the mediation process that the Company has previously disclosed, 3M will contribute a total amount of $6.01 billion between 2023 and 2029, which is structured under the Settlement to include $5.01 billion in cash consideration and $1 billion in 3M common stock, par value $0.01 per share.&quot; This is what the company told investors on that date.</summary>
  </entry>
  <entry>
    <title>3M Co stated a settlement amount of $10,300,000,000: Aqueous Film-Forming Foams Products Liability Litigation</title>
    <id>tag:perfectplaintiff.com,2023-06-22:settlement/2873/2023-06-22/5</id>
    <link rel="alternate" type="text/html" href="https://perfectplaintiff.com/mass-torts/aqueous-film-forming-foams-products-liability-litigation-mdl-2873/"/>
    <updated>2023-06-22T00:00:00Z</updated>
    <summary>In a form 8-K filed with the Securities and Exchange Commission on 2023-06-22, 3M Co stated: &quot;Financial Considerations Under the terms of the settlement, 3M has agreed to contribute up to a present value of $10.3 billion, payable over 13 years. 3M expects to record a pre-tax charge of approximately $10.3 billion in the second quarter of 2023 and to reflect it as an adjustment in arriving at results, adjusted for special items.&quot; This is what the company told investors on that date.</summary>
  </entry>
  <entry>
    <title>Teva Pharmaceutical Industries Ltd stated a settlement amount of $4,250,000,000: National Prescription Opiate Litigation</title>
    <id>tag:perfectplaintiff.com,2023-06-08:settlement/2804/2023-06-08/6</id>
    <link rel="alternate" type="text/html" href="https://perfectplaintiff.com/mass-torts/national-prescription-opiate-litigation-mdl-2804/"/>
    <updated>2023-06-08T00:00:00Z</updated>
    <summary>In a form 8-K filed with the Securities and Exchange Commission on 2023-06-08, Teva Pharmaceutical Industries Ltd stated: &quot;Under the terms of the Nationwide Opioids Settlement Agreement, the Company will pay the participating states and subdivisions up to $4.25 billion (including already settled cases, excluding the settlement with the state of Nevada, which is discussed below), spread over 13 years.&quot; This is what the company told investors on that date.</summary>
  </entry>
  <entry>
    <title>Chemours Co stated a settlement amount of $1,185,000,000: Aqueous Film-Forming Foams Products Liability Litigation</title>
    <id>tag:perfectplaintiff.com,2023-06-02:settlement/2873/2023-06-02/7</id>
    <link rel="alternate" type="text/html" href="https://perfectplaintiff.com/mass-torts/aqueous-film-forming-foams-products-liability-litigation-mdl-2873/"/>
    <updated>2023-06-02T00:00:00Z</updated>
    <summary>In a form 8-K filed with the Securities and Exchange Commission on 2023-06-02, Chemours Co stated: &quot;Under the MOU, the Companies will collectively establish and contribute a total of $1.185 billion to a settlement fund (&quot;water district settlement fund&quot;).&quot; This is what the company told investors on that date.</summary>
  </entry>
  <entry>
    <title>Altria Group, Inc. stated a settlement amount of $235,000,000: Juul Labs, Inc., Marketing, Sales Practices, and Products Liability Litigation</title>
    <id>tag:perfectplaintiff.com,2023-05-10:settlement/2913/2023-05-10/8</id>
    <link rel="alternate" type="text/html" href="https://perfectplaintiff.com/mass-torts/juul-labs-inc-marketing-sales-practices-and-products-liability-litigation-mdl-2913/"/>
    <updated>2023-05-10T00:00:00Z</updated>
    <summary>In a form 8-K filed with the Securities and Exchange Commission on 2023-05-10, Altria Group, Inc. stated: &quot;On May 10, 2023, Altria entered into a term sheet pursuant to which, among other things, we agreed to settle at least 6,000 JUUL-related cases for an aggregate amount of $235 million, including attorneys' fees.&quot; This is what the company told investors on that date.</summary>
  </entry>
  <entry>
    <title>Meta Platforms, Inc. stated a settlement amount of $725,000,000: Facebook, Inc., Consumer Privacy User Profile Litigation</title>
    <id>tag:perfectplaintiff.com,2023-02-02:settlement/2843/2023-02-02/9</id>
    <link rel="alternate" type="text/html" href="https://perfectplaintiff.com/mass-torts/facebook-inc-consumer-privacy-user-profile-litigation-mdl-2843/"/>
    <updated>2023-02-02T00:00:00Z</updated>
    <summary>In a form 10-K filed with the Securities and Exchange Commission on 2023-02-02, Meta Platforms, Inc. stated: &quot;With respect to the multiple putative class actions filed against us beginning on March 20, 2018 alleging fraud and violations of consumer protection, privacy, and other laws in connection with the same matters, several of the cases brought on behalf of consumers in the United States were consolidated in the U.S. District Court for the Northern District of California. On September 9, 2019, the court granted, in part, and denied, in part, our motion to dismiss the consolidated putative consumer class action. On December 22, 2022, the parties entered into a settlement agreement to resolve the lawsuit, which provides for a payment of $725 million by us and is subject to court approval.&quot; This is what the company told investors on that date.</summary>
  </entry>
  <entry>
    <title>Walmart Inc. stated a settlement amount of $3,100,000,000: National Prescription Opiate Litigation</title>
    <id>tag:perfectplaintiff.com,2022-11-15:settlement/2804/2022-11-15/10</id>
    <link rel="alternate" type="text/html" href="https://perfectplaintiff.com/mass-torts/national-prescription-opiate-litigation-mdl-2804/"/>
    <updated>2022-11-15T00:00:00Z</updated>
    <summary>In a form 8-K filed with the Securities and Exchange Commission on 2022-11-15, Walmart Inc. stated: &quot;Both frameworks provide for the possibility of settling substantially all of the opioid claims that have been or could be made against it by states, political subdivisions, and tribes for up to approximately $3.1 billion, which includes amounts for remediation of alleged harms as well as attorneys' fees and costs (the &quot;Settlement Amount&quot;).&quot; This is what the company told investors on that date.</summary>
  </entry>
  <entry>
    <title>Walgreens Boots Alliance, Inc. stated a settlement amount of $4,790,000,000: National Prescription Opiate Litigation</title>
    <id>tag:perfectplaintiff.com,2022-11-02:settlement/2804/2022-11-02/11</id>
    <link rel="alternate" type="text/html" href="https://perfectplaintiff.com/mass-torts/national-prescription-opiate-litigation-mdl-2804/"/>
    <updated>2022-11-02T00:00:00Z</updated>
    <summary>In a form 8-K filed with the Securities and Exchange Commission on 2022-11-02, Walgreens Boots Alliance, Inc. stated: &quot;Under the Settlement Framework with the Settling States, the Company expects to settle all opioid claims against it by such Settling States for up to approximately $4.79 billion in remediation payments to be paid out over fifteen (15) years.&quot; This is what the company told investors on that date.</summary>
  </entry>
</feed>
